Bg pattern

MIRAZUL 1.25 mg/ml EYE DROPS SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use MIRAZUL 1.25 mg/ml EYE DROPS SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

Mirazul 1.25 mg/ml Eye Drops Solution

Phenylephrine Hydrochloride

Read the entire package leaflet carefully before starting to use this medication, as it contains important information for you.

Follow the administration instructions for the medication contained in this package leaflet or as indicated by your doctor, pharmacist, or nurse.

  • Keep this package leaflet, as you may need to read it again.
  • If you need advice or more information, consult your pharmacist.
  • If you experience side effects, consult your doctor, pharmacist, or nurse, even if they are side effects not listed in this package leaflet. See section 4.
  • You should consult a doctor if it worsens or does not improve after 5 days.

Contents of the Package Leaflet:

  1. What Mirazul is and what it is used for
  2. What you need to know before starting to use Mirazul
  3. How to use Mirazul
  4. Possible side effects
  5. Storage of Mirazul
  6. Package Contents and Additional Information

1. What Mirazul is and what it is used for

Mirazul belongs to the group of medications known as ocular decongestants.

Phenylephrine hydrochloride is a medication that belongs to the group of sympathomimetics used as decongestants, it has a vasoconstrictor effect (causes narrowing of blood vessels), producing rapid and prolonged decongestion, relieving eye irritations.

Mirazul is an eye drop solution indicated to relieve eye irritation caused by smoke, air, dust, pool chlorine, seawater, polluted environments, contact lenses, cosmetics, eye fatigue, etc. in adults.

You should consult a doctor if it worsens or does not improve after 5 days.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before starting to use Mirazul

Do not use Mirazul:

  • If you are allergic to phenylephrine hydrochloride or any of the other components of this medication (listed in section 6).
  • If you have glaucoma (increased pressure inside the eye), as the vasoconstrictor action of phenylephrine may lead to a transient increase in intraocular pressure (pressure of the eye fluids).
  • If you are taking any monoamine oxidase inhibitor (MAOI) medication (such as some antidepressants) or have taken it up to 21 days before using Mirazul.
  • If you have any severe thyroid disease (overactive thyroid gland).
  • If you have dry rhinitis (inflammation of the nasal mucosa).
  • In children under 12 years of age.

Warnings and Precautions

Consult your doctor, pharmacist, or nurse before starting to use Mirazul.

  • If you have high blood pressure.
  • If you have advanced arteriosclerosis (hardening of the arteries).
  • If you have orthostatic hypotension (decrease in blood pressure when changing position).
  • If you have long-term insulin-dependent diabetes.
  • If you have heart disease, including severe ischemic cardiopathy (transient decrease in blood circulation to the heart).

During administration, care should be taken not to touch the dropper tip to the eye, touch it with hands, or with any other object. It should be closed immediately after use.

If there is no improvement after 5 days of treatment or if symptoms worsen when using the medication, its use should be discontinued and a doctor consulted.

Chronic use of this medication can cause rebound congestion in the eye.

When patients are not yet accustomed to contact lenses, they should not use this medication for more than 5 consecutive days without consulting a doctor, in order to avoid masking possible eye irritation due to incorrect fitting of the lenses.

If eye pain, headache, blurred vision, or changes in vision, sensitivity of the eyes to light, or eye redness occur, a doctor should be consulted.

Children

Mirazul should not be used in children under 12 years of age, as children seem to be more sensitive to the risk of serious side effects.

Mirazul is not recommended in children between 12 and 18 years of age, as there is a lack of adequate clinical experience.

Using Mirazul with Other Medications

Inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication.

  • Tricyclic antidepressants (amitriptyline, doxepin, trimipramine) and MAOIs (isocarboxazid, iproniazid, moclobemide), which are medications for treating depression, reserpine, and guanethidine (medication for reducing blood pressure), may increase the action of this medication.
  • This medication is incompatible with the local anesthetic butacaine.
  • The mydriatic response (increase in pupil dilation) of phenylephrine hydrochloride is reduced when the patient is treated simultaneously with levodopa (medication for treating Parkinson's disease).

Pregnancy and Breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.

Since the risk to the fetus cannot be excluded, the use of Mirazul is not recommended during pregnancy.

Breastfeeding women should consult their doctor before using this medication, as it is not known with certainty whether phenylephrine hydrochloride passes into breast milk.

Driving and Using Machines

Mirazul has a mydriatic effect (abnormal dilation of the pupil with iris immobility) that increases with the dose. This medication may cause disorders in visual accommodation (eye adaptation), and therefore, a decrease in reaction time. Therefore, driving or using machinery after administration is not recommended.

Mirazul Contains Benzoic Acid

This medication may be slightly irritating to the skin, eyes, and mucous membranes because it contains benzoic acid.

Avoid contact with soft contact lenses. It changes the color of soft contact lenses.

Remove contact lenses before application and wait at least 15 minutes before putting them back on.

3. How to Use Mirazul

Follow the administration instructions for the medication contained in this package leaflet or as indicated by your doctor or pharmacist. In case of doubt, ask your doctor, pharmacist, or nurse.

The recommended dose is 1-2 drops in each eye, as needed, 3 or 4 times a day if necessary.

How to use Mirazul:

Mirazul is used via the ocular route

  1. Wash your hands before using Mirazul.
  2. Take the open container and hold it with one hand, between the thumb and index finger.
  3. Using the index finger of the other hand, separate the lower eyelid of the eye downward.
  4. Gently press the container, allowing one or two drops to fall into the eye
  5. After application, keep the eye closed for a few moments to facilitate the distribution of the liquid over the entire eye surface
  6. Repeat the steps above for the other eye.
  7. Close the container well after each use.

If You Use More Mirazul Than You Should

If you have used more Mirazul than you should, it could lead to manifestations such as elevated blood pressure, increased or decreased heart rate.

In case of overdose or accidental ingestion, go to a medical center indicating the product and the amount ingested or consult the Toxicology Information Service: Phone: 91.562.04.20.

If you have any other doubts about the use of this product, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible Side Effects

Like all medications, this medication can cause side effects, although not everyone will experience them.

The following side effects may occur, whose frequency cannot be defined with precision: allergic conjunctivitis, mydriasis (pupil dilation), alterations in visual accommodation, eye irritation, or contact dermatitis.

Reporting Side Effects

If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a side effect not listed in this package leaflet. You can also report them directly through the Spanish Medication Pharmacovigilance System: www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.

5. Storage of Mirazul

Keep this medication out of sight and reach of children.

Do not use this medication after the expiration date that appears on the container after "EXP". The expiration date is the last day of the month indicated.

Discard the product one month after opening the container.

Do not use Mirazul if you notice that the solution changes color or becomes cloudy.

Medications should not be thrown down the drain or into the trash. Ask your pharmacist how to dispose of the containers and medications you no longer need. This will help protect the environment.

6. Package Contents and Additional Information

Mirazul Composition

  • The active ingredient of Mirazul is phenylephrine hydrochloride. Each ml of solution contains 1.25 mg of phenylephrine hydrochloride.
  • The other components are disodium phosphate, benzoic acid (E-210), ethanol 0.0037% v/v, chlorobutanol, benzyl alcohol, terpineol, methyl blue, sodium chloride, and water for injection.

Product Appearance and Package Contents

Mirazul is an eye drop solution presented in a 10 ml bottle.

Marketing Authorization Holder and Manufacturer:

Holder:

LABORATORIO DE APLICACIONES FARMACODINÁMICAS, S.A.

Grassot, 16 – 08025 Barcelona (Spain)

Date of the Last Revision of this Package Leaflet:June 2021

Detailed information about this medication is available on the European Medicines Agency website: http://www.ema.europa.eu/, and on the Spanish Agency for Medicines and Health Products (AEMPS) website: http://www.aemps.gob.es/

Online doctors for MIRAZUL 1.25 mg/ml EYE DROPS SOLUTION

Discuss questions about MIRAZUL 1.25 mg/ml EYE DROPS SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for MIRAZUL 1.25 mg/ml EYE DROPS SOLUTION?
MIRAZUL 1.25 mg/ml EYE DROPS SOLUTION does not require a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in MIRAZUL 1.25 mg/ml EYE DROPS SOLUTION?
The active ingredient in MIRAZUL 1.25 mg/ml EYE DROPS SOLUTION is phenylephrine. This information helps identify medicines with the same composition but different brand names.
Who manufactures MIRAZUL 1.25 mg/ml EYE DROPS SOLUTION?
MIRAZUL 1.25 mg/ml EYE DROPS SOLUTION is manufactured by Laboratorio De Aplicaciones Farmacodinamicas S.A.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of MIRAZUL 1.25 mg/ml EYE DROPS SOLUTION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether MIRAZUL 1.25 mg/ml EYE DROPS SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to MIRAZUL 1.25 mg/ml EYE DROPS SOLUTION?
Other medicines with the same active substance (phenylephrine) include ALERGOFTAL 0.25 mg/ml + 5 mg/ml EYE DROPS SOLUTION, CENTILUX 0.25 mg/ml EYE DROPS SOLUTION, LUMOBRY 0.25 mg/ml EYE DROPS SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media